risks of glp 1 GLP-1 Agonists In Obesity Why do patients stop GLP-1

Compared with SGLT-2 inhibitor use, GLP-1 receptor agonist use was not associated with an increased risk of pulmonary aspiration (pooled risk ratio 0.98, 95% CI 0.73 to 1.31), although it was associated with a higher risk for discontinuation of endoscopy (1.99, 1.56 to 2.53)

Considerations regarding adverse effects and contraindications for different drug classes are provided to help guide treatment decision-making when considering pharmacotherapy for weight management in patients with obesity.

By Vital Nutrients

GLP-1 medications give most people sticker shock

For the 40% of American adults with obesity, glucagon-like peptide-1 receptor agonists, or GLP-1 drugs, may offer hopebut the cost can put them out of reach for many patients

But the range was wide some lost over 25%, some less than 5%.